Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-Day Versus 4-Week Esomeprazole for Unexplained Dyspepsia
2025-524044-35-00Phase 4Authorised
- Sponsor
- Landspitali
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esomeprazole in functional dyspepsia (FD) (2 arms), sponsored by Landspitali. Primary endpoint: Change in mean daily modified Glasgow Dyspepsia Severity Score (GDSS) from Week 1 to Weeks 2-4. Planned start Feb 2026; status: authorised.
02
Drugs
esomeprazole
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on 2025-524044-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524044-35-00.